Publication | Closed Access
Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial
129
Citations
19
References
2008
Year
Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1